Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid

The Epidemiology, Diagnosis, and Management of Aristolochic Acid Nephropathy

(2013) M. Refik Gökmen et al.   ANNALS OF INTERNAL MEDICINE

Risk Assessment of Upper Tract Urothelial Carcinoma Related to Aristolochic Acid

(2013) F. Wu et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Enzymes Metabolizing Aristolochic Acid and their Contribution to the Development of Aristolochic Acid Nephropathy and Urothelial Cancer

(2013) Marie Stiborova et al.   CURRENT DRUG METABOLISM

Evaluation of the cytotoxicity and genotoxicity of aristolochic acid I – A component of Aristolochiaceae plant extracts used in homeopathy

(2013) Dana Nitzsche et al.   ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY

Is aristolochic acid nephropathy a widespread problem in developing countries?

(2013) Johanna Michl et al.   JOURNAL OF ETHNOPHARMACOLOGY

Variation in Presentation and Presence of DNA Adducts and p53 Mutations in Patients with Endemic Nephropathy - an Environmental Form of the Aristolochic Acid Nephropathy

(2013) Sandra Karanovic et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool

(2013) S. L. Poon et al.   Science Translational Medicine

Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing

(2013) M. L. Hoang et al.   Science Translational Medicine

THE ROLE OF BIOTRANSFORMATION ENZYMES IN THE DEVELOPMENT OF RENAL INJURY AND UROTHELIAL CANCER CAUSED BY ARISTOLOCHIC ACID: URGENT QUESTIONS AND DIFFICULT ANSWERS

(2012) Marie Stiborova et al.   BIOMEDICAL PAPERS-OLOMOUC

Biomonitoring of Aristolactam-DNA Adducts in Human Tissues Using Ultra-Performance Liquid Chromatography/Ion-Trap Mass Spectrometry

(2012) Byeong Hwa Yun et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease

(2012) Arthur P. Grollman   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania

(2012) Heinz H. Schmeiser et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

Aristolochic acid-associated urothelial cancer in Taiwan

(2012) C.-H. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I

(2012) Katerina Levova et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Possible role of mtDNA depletion and respiratory chain defects in aristolochic acid I-induced acute nephrotoxicity

(2012) Zhenzhou Jiang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling

(2012) Volker M. Arlt et al.   TOXICOLOGY LETTERS

Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats

(2012) Alice Zachařová et al.   XENOBIOTICA

Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat

(2011) Rostislav Večeřa et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Aristolochic Acid I Metabolism in the Isolated Perfused Rat Kidney

(2011) Horacio A. Priestap et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Role of P450 1A1 and P450 1A2 in Bioactivation versus Detoxication of the Renal Carcinogen Aristolochic Acid I: Studies inCyp1a1(−/−),Cyp1a2(−/−), andCyp1a1/1a2(−/−)Mice

(2011) Volker M. Arlt et al.   CHEMICAL RESEARCH IN TOXICOLOGY

The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases

(2011) Marie Stiborová et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

TP53 Mutational signature for aristolochic acid: an environmental carcinogen

(2011) Masaaki Moriya et al.   INTERNATIONAL JOURNAL OF CANCER

Glutathione S-transferases T1 null genotype is associated with susceptibility to aristolochic acid nephropathy

(2011) Bicheng Chen et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid

(2011) Bojan Jelaković et al.   KIDNEY INTERNATIONAL

Role of Cytochromes P450 1A1/2 in Detoxication and Activation of Carcinogenic Aristolochic Acid I: Studies with the Hepatic NADPH:Cytochrome P450 Reductase Null (HRN) Mouse Model

(2011) Kateřina Levová et al.   TOXICOLOGICAL SCIENCES

Bioactivation versus Detoxication of the Urothelial Carcinogen Aristolochic Acid I by Human Cytochrome P450 1A1 and 1A2

(2011) Marie Stiborová et al.   TOXICOLOGICAL SCIENCES

Inhibition of Renal NQO1 Activity by Dicoumarol Suppresses Nitroreduction of Aristolochic Acid I and Attenuates its Nephrotoxicity

(2011) Min Chen et al.   TOXICOLOGICAL SCIENCES

Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model

(2010) Jill E. Kucab et al.   FEBS Journal

Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice

(2010) Volker M. Arlt et al.   INTERNATIONAL JOURNAL OF CANCER

Toxicities of aristolochic acid I and aristololactam I in cultured renal epithelial cells

(2010) Ji Li et al.   TOXICOLOGY IN VITRO

The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells

(2009) Jan Vondráček et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Detoxification of aristolochic acid I by O-demethylation: Less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents

(2009) Shinya Shibutani et al.   INTERNATIONAL JOURNAL OF CANCER

Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2—A global assessment based on bibliographic sources

(2009) Michael Heinrich et al.   JOURNAL OF ETHNOPHARMACOLOGY

p53 mutations as fingerprints for aristolochic acid – an environmental carcinogen in endemic (Balkan) nephropathy

(2009) Neda Slade et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Late Onset of Bladder Urothelial Carcinoma After Kidney Transplantation for End-Stage Aristolochic Acid Nephropathy: A Case Series With 15-Year Follow-up

(2008) Anne Lemy et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Generation of a ‘humanized’ hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mouse line harboring the poor-affinity aryl hydrocarbon receptor

(2008) Zhanquan Shi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

TP53mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours

(2008) Tatiana Nedelko et al.   INTERNATIONAL JOURNAL OF CANCER

Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity

(2008) Y. Xiao et al.   KIDNEY INTERNATIONAL

Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid

(2008) M. Stiborová et al.   KIDNEY INTERNATIONAL

Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy

(2007) Marie Stiborová et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: Studies with the hepatic NADPH:Cytochrome P450 reductase null mouse

(2007) Marie Stiborová et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY